• Home
  • Search Results
  • Complementary methods provide evidence for the expression of CXCR7 on human B cells.

Complementary methods provide evidence for the expression of CXCR7 on human B cells.

Proteomics (2012-05-25)
Marie-Luise Humpert, Manuel Tzouros, Sylvia Thelen, Alexandre Bignon, Angélique Levoye, Fernando Arenzana-Seisdedos, Karl Balabanian, Françoise Bachelerie, Hanno Langen, Marcus Thelen

PTMs of extracellular domains of membrane proteins can influence antibody binding and give rise to ambivalent results. Best proof of protein expression is the use of complementary methods to provide unequivocal evidence. CXCR7, a member of the atypical chemokine receptor family, mainly functions as scavenger for the chemokines CXCL12 and CXCL11. The expression of CXCR7 on nonhematopoietic cells and neoplasms is widely accepted, however, its expression on leukocytes was recently challenged. To solve the dissent, we thoroughly analyzed the expression of CXCR7 on human B cells. We validated the efficiency of different epitope-specific monoclonal antibodies to detect CXCR7 on transfected cells and primary human B cells. The specificity of the used antibodies was further confirmed by an experimentally independent double labeling approach. Examination of CXCR7-dependent scavenging of fluorescent-labeled CXCL12 revealed functional expression of the receptor on human B cells. Moreover, real-time PCR analysis of CXCR7 mRNA showed the presence of transcripts in human leukocytes. Finally, two CXCR7-specific peptides were identified by MS in immunoprecipitates from primary human B cells. Thus, we present a strategy based on combined proteomic and functional approaches that can be used to solve dissents on protein expression, i.e. demonstrating the expression of CXCR7 on human leukocytes.

Product Number
Product Description

Atto 565 NHS ester, BioReagent, suitable for fluorescence, ≥70.0% (coupling to amines)
Atto 565, BioReagent, suitable for fluorescence, ≥75% (sum of isomers, HPCE/HPLC)
Atto 565-Biotin, BioReagent, suitable for fluorescence, ≥90% (HPCE)
Atto 565 maleimide, BioReagent, suitable for fluorescence
Atto 565 azide, BioReagent, suitable for fluorescence, ≥80.0% (HPCE)
Atto 565 iodoacetamide, BioReagent, suitable for fluorescence

Social Media

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon


Research. Development. Production.

We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved.

Reproduction of any materials from the site is strictly forbidden without permission.